A highly mutated COVID-19 variant showing resistance to both vaccines and natural immunity has spread to 25 states, prompting federal health officials to raise concerns about potential public health risks as genomic surveillance reveals ongoing viral evolution.
Immune-Evasive Strain Detected Across America
The SARS-CoV-2 BA.3.2 variant carries 70 to 75 mutations in its spike protein, the structure COVID uses to enter human cells. Federal researchers confirmed the strain through nasal swabs from four travelers, clinical samples from five patients, three airplane wastewater samples, and 132 wastewater surveillance samples spanning 25 states. The Centers for Disease Control and Prevention has been tracking BA.3.2 through its Traveler-Based Genomic Surveillance program since the first American case appeared in June 2025 from a Netherlands traveler.
Dr. Marc Siegel, Fox News senior medical analyst, explained the variant demonstrates immune escape characteristics, meaning mutations may help it partially evade existing immunity from vaccines or prior infection. The strain differs genetically from JN.1 lineages that circulated throughout America since January 2024. Weekly detections rose to approximately 30 percent of cases in Denmark, Germany, and the Netherlands between November 2025 and January 2026. At least 23 countries have reported BA.3.2 as of February 11, according to CDC research published in the Morbidity and Mortality Weekly Report.
Unknown Severity Sparks Monitoring Concerns
Siegel noted scientists do not yet know how virulent the variant proves in infected patients. The prevalence may exceed current data suggests, as many countries maintain limited genomic detection and surveillance capacities. Researchers identified two emerging sublineages, BA.3.2.1 and BA.3.2.2, indicating continued viral evolution. The strain first appeared in September 2025 before spreading internationally.
Federal Response and Public Health Impact
CDC researchers emphasized ongoing genomic surveillance remains necessary to monitor the virus evolution and assess potential community-wide impact. Because BA.3.2 mutations in the spike protein may weaken protection from vaccination or prior infection, health officials continue tracking transmission patterns. Siegel acknowledged concern exists that the variant could represent significant public health risk, though current prevalence remains too low to predict community-wide effects. The highly mutated nature of BA.3.2 distinguishes it from widely circulated subvariants, making it a priority for federal health monitoring programs focused on protecting American communities.